- Finalist for Research Poster Presentation Award:
Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?
- Do companies’ market access training capabilities address the needs of today’s complex payer marketplace?
- Exploring biosimilar market access considerations across europe
- Has the new NICE appraisal process for oncology drugs delivered faster patient access to innovative treatments?
- What are the key considerations for seeking payer scientific advice in the EU?
Come along and meet the team at booth 901, discuss our findings or have a chat about your pricing and market access challenges.
Looking forward to seeing you there.